Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06966479 · ClinicalTrials.gov registry record · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
A Phase 2 study of Severe Asthma, sponsored by Upstream Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 436
- Enrollment target
- 20
- Study locations
NCT06966479: Recruiting Phase 2 study of Severe Asthma, sponsored by Upstream Bio.
NCT06966479 is a Phase 2 study of Severe Asthma that is actively recruiting participants, run by Upstream Bio. The registered enrollment target is 436 participants, below the 3,806-participant average among 9 other Severe Asthma trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06966479, a Phase 2 study of Severe Asthma, is actively recruiting participants, sponsored by Upstream Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 436 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
Primary Outcome
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Verekitug
Study Locations (20)
Florida
- Advance Pharma Research - Cutler Bay
- Phoenix Medical Research - Miami
- Research Institute of South Florida - Miami
- Health and Life Research Institute, LLC - Miami
- Nouvelle Clinical Research - Miami
- Edward Jenner Research Group, LLC - Plantation
- R&B Medical Center - Tampa
- Clinical Site Partners dba Flourish research - Winter Park
California
- Kern Research, Inc. - Bakersfield
- California Medical Research Associates Inc. - Northridge
- Integrated Research of Inland Inc - Upland
- Allergy & Asthma Clinical Research - Walnut Creek
- Allianz Research Institute - Westminster
Michigan
- Pulmonary Research Institute of Southeast Michigan (PRISM) - Farmington Hills
- AA MRC - Flint
Idaho
- Treasure Valley Medical Research - Boise
Maryland
- Chesapeake Clinical Research Inc - White Marsh
Nevada
- M3 Wake Research - Las Vegas
New York
- Urban Health Plan INC - The Bronx
Ohio
- Toledo Institute of Clinical Research Inc - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2025-05-21 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06966479 shows while recruiting
NCT06966479 is an interventional study that assigns participants to a tested intervention. The registered 436 participants enrollment target is mid-sized for trials with a published cap, below the 3,806-participant average among 9 other Severe Asthma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06966479 names 20 study sites across 8 states, led by Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06966479 about?
NCT06966479 is a clinical study titled "A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)". The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).
What is the current status of trial NCT06966479?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 436 participants. The study started on 2025-05-21. Estimated completion is 2027-09.
What conditions does trial NCT06966479 study?
This clinical trial studies the following conditions: Severe Asthma.
What interventions are being tested in trial NCT06966479?
The interventions under investigation include: Placebo (DRUG), Verekitug (DRUG).
Who is sponsoring clinical trial NCT06966479?
This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06966479 being conducted?
This trial has 20 study locations across California, Florida, Idaho, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06966479's enrollment target sits among peer trials
436 5th of 9 higher than 5 of 9 other Severe Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
ACTIVE NOT RECRUITING · Phase 2
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
RECRUITING · Phase 3
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT07318493 · 436 participants · NA
Antiseptic-Coated Sutures and Pancreatic Fistula Risk After Pancreatoduodenectomy
- NCT05563220 · 435 participants · Phase 1
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI